donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02142 HBM HOLDINGS-B > Company Executives
02142 HBM HOLDINGS-B
4.070
-0.030-0.73%
NamePositionSalaryService DateEducationAgeGenderUpdated
王劲松Executive director,Chairman of the nomination committee,CEO,Remuneration committee member,Chairman of the board,Authorized representative13.27M07/01/2016Doctor58male05/06/2022
裘育敏Non-Executive Director,Member of the audit committee--12/01/2016Master49male05/06/2022
Humphrey GardnerChief Medical Officer--04/14/2022Doctor--male05/26/2022
王俊峰Non-Executive Director--03/01/2018Master48male05/06/2022
陈维维Non-Executive Director11.00K06/09/2021Master56female05/06/2022
戎一平Executive director--05/05/2022Doctor45male05/06/2022
Robert Irwin KamenIndependent non-executive director,Nominating committee member303.00K12/01/2016Doctor78male05/06/2022
叶小平Nominating committee member,Chairman of the remuneration committee,Member of the audit committee,Independent non-executive director--11/30/2020Doctor59male05/06/2022
邱家赐Independent non-executive director,Remuneration committee member,Chairman of the audit committee--06/09/2021Bachelor64male05/06/2022
陈颖颖CFO--07/20/2021Doctor47female05/06/2022
刘礼乐Senior Vice President,Person in charge of technology platform and Suzhou operation--10/01/2018Bachelor60male05/06/2022
阙红Chief technology officer--06/01/2021Doctor57--05/06/2022
吕颖一Joint company secretary--07/13/2021Bachelor33male05/06/2022
徐伟豪Chief Strategy Officer--12/01/2021Master39male05/06/2022
傅裕Joint company secretary--07/13/2021Bachelor30male05/06/2022
陶晓路Senior Vice President--07/01/2020Doctor48female05/06/2022
Company Overview More
Heplatinum Pharmaceutical Holdings Co., Ltd. is an investment holding company mainly engaged in the development of innovative therapies in the field of tumor immunology and immune diseases. The company's products include bartolizumab, mainly for immune thrombocytopenia, thyroid associated ophthalmopathy, myasthenia gravis, optic neuromyelitis spectrum diseases, and tenacil, mainly for dry eye diseases. In addition, the company also studies and develops tumor immunization product lines, including internally developed new-generation tumor immune assets for the treatment of immune desert, immune rejection and inflammatory tumors.
CEO: Jingsong Wang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...